Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,511.24 +329.21 (+0.50%) CMC Crypto 200
1,382.10 -35.77 (-2.52%)
RGNX Jan 2025 20.000 call
| Previous close | 1.9500 |
| Open | 1.9500 |
| Bid | 0.4500 |
| Ask | 2.7000 |
| Strike | 20.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.9500 - 1.9500 |
| Contract range | N/A |
| Volume | |
| Open interest | 31 |
PR NewswireREGENXBIO Announces Leadership Transition
REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as REGENXBIO
- PR Newswire
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.
Simply Wall St.It Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights REGENXBIO will host its Annual General Meeting on 31st of May Total pay for CEO Ken Mills includes...
